ImmunityBio (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced that the European Commission has ...

ImmunityBio will submit long-term safety and efficacy data to the European Medicines Agency as part of the conditional ...

ImmunityBio shares rose after the company said it got conditional marketing authorization from European regulators for its drug to treat bladder cancer. The stock climbed 32% to $7.94 on Wednesday.

Investigators reported results from the first randomized controlled trial of office-based laser photocoagulation to standard TURBT for low-grade Ta bladder tumors.

AstraZeneca has received a positive recommendation from the National Institute for Health and Care Excellence for durvalumab, ...

Bladder cancer frequently announces itself through symptoms that patients dismiss as minor urinary issues, and that delay ...

ImmunityBio commands a premium valuation on the promise of Anktiva, a chemo-free immunotherapy platform showing early ...

TAR-200 achieved an 82% tumor elimination rate in high-risk non-muscle-invasive bladder cancer patients resistant to previous treatments. The device releases gemcitabine into the bladder over three ...

Please provide your email address to receive an email when new articles are posted on . A urinary DNA methylation test outperformed the nuclear matrix protein 22 test or urine cytology test.

Now, it’s worth noting Stock Advisor’s total average return is 889 % — a market-crushing outperformance compared to 193% for the S&P 500. Don't miss the latest top 10 list, available with Stock ...

The extent of the bladder cancer — how far it has spread — matters. Your care team needs to know if your cancer sits on or in the first lining of your bladder (non-muscle invasive), if it goes into ...